EV/EBITDA Multiple: Pluristem Therapeutics (PLUR)

Corporate company logo of pluri-biotech.com (PLUR)

Pluri Inc. (PLUR) focuses on the development of cell therapy and CDMO services, as well as the creation of cultured meat and the treatment of blood diseases. This chart available on GURU.Markets with the 0.00 indicator links these achievements to the diversification of the business between medicine and agrotech to minimize risks. The firm's environmental profile is limited by strict control over the disposal of laboratory waste.

PLUR (Pluri) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/11/2026

pluri-biotech.com (PLUR) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart Pluri|PLUR - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization PLUR|PLUR - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Pluri|PLUR - Total Net Assets|Market Capitalization to Book Value Ratio pluri-biotech.com|PLUR - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Pluri Inc.|PLUR - Long-Term Debt to Equity|Short-Term Debt to Equity Pluri|PLUR - Company Cumulative Debt|Debt to Book Capitalization Ratio PLUR|PLUR - Company Long-Term Debt|Company Short-Term Debts Pluri|Quick Liquidity pluri-biotech.com
- net income and valuation multiples indicators:
PLUR - Net Financial Result|Expected Profit Pluri Inc.|PLUR - Price to Earnings Ratio|Future Price to Earnings Pluri|PLUR - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PLUR|PLUR - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Pluri|PLUR - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months pluri-biotech.com|PLUR - Earnings per share increase in current year|Earnings growth forecast for next year Pluri Inc.
Initial company analysis:PLUR (Pluri Inc)
Product sample of Pluri

This ratio compares the total enterprise value, including debt obligations, with operating profit, allowing investors to determine the extent of an asset's overvaluation relative to its ability to generate cash flow. When analyzing the trend level of the EV/EBITDA for Pluri Inc. (PLUR), it is essential to consider that this balance depends directly on the efficiency of commercializing cell technologies and reducing the cost of scalable bioproducts.

Who Pluri Inc. competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Corp|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (soleno.life)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altimmune Corp (ALT)|Enterprise Value to EBITDA Ratio Aardvark Pharma AARD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Company Value to Operating Income Before Depreciation Ratio|BMEA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|QNCX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GUTS (Fractyl) - Enterprise Value to EBITDA Ratio|vTv Therapeutics (VTVT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agape ATP Corp|SYBX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple LPCN|Total Company Value to Operating Income Before Depreciation Ratio matinasbiopharma.com|Spruce Biosciences - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GLTO|Carmell Corporation - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio lumos-pharma.com LUMO|Organovo (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation RDUS